Biophysics in drug discovery: impact, challenges and opportunities

Jean‐Paul Renaud(Institut de génétique et de biologie moléculaire et cellulaire), Herbert Nar(Boehringer Ingelheim (Germany)), Ursula Egner(Nuvisan (Germany)), Michael Hennig(Roche (Switzerland)), Chun‐wa Chung(GlaxoSmithKline (United Kingdom)), Roderick E. Hubbard(Granta Design (United Kingdom)), U. Helena Danielson(Uppsala University)
Nature Reviews Drug Discovery
August 12, 2016
10.1038/nrd.2016.123
Cited by 383

Related Papers

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
A specific antidote for dabigatran: functional and structural characterization
|Blood|2013|562
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
|Journal of Medicinal Chemistry|2007|285